Tuberculosis (TB) remains one of the major infectious diseases of mankind although drugs for its treatment have been available for nearly 60 years. The standard short-course 6-month regimen used since about 1980 has helped to save millions of lives, but co-infection with HIV has had a devastating effect on the epidemic, and multidrug-resistant TB is a growing problem, particularly in communities with a high incidence of HIV. Following the declaration by the WHO in the early 1990s that TB was ‘a global health emergency’, interest in TB research and the development of new drugs has increased significantly.

This volume reviews anti-TB chemotherapy with the emphasis on the actions and pharmacology of existing drugs and the development and evaluation of new agents. A close look is taken at new research regarding our existing drugs by some of the best-known specialists in the field, and historical aspects of these agents are reviewed from a modern perspective. The prospects for the introduction of new drugs and different approaches of how to assess them in adults and in children are discussed in detail. Several papers address the problems associated with drug resistance, its spread and diagnosis.

Compiled by two editors from Cape Town, which has a particularly high incidence of TB and is a centre of tuberculosis research, this publication is an indispensable reference for anyone involved in the management of TB either as a researcher, clinician or administrator, and those working in drug development.

Contents

Retrospectoscope

History of Drug Discovery: Early Evaluation Studies and Lessons Learnt from Them: Ahmad, Z.; Makaya, N.H.; Grosset, J.

Tuberculosis Treatment Trials Past and Present: Old and New Challenges: Nunn, N.

Present Treatment

The Rifamycins: Renewed Interest in an Old Drug Class: Burman, W.; Dooley, K.E.; Nuernberger, E.L.

Isoniazid Pharmacokinetics and Efficacy in Adults and Children: Donald, P.R.; Schaaf, H.S.

Recent Developments in the Study of Pyrazinamide: An Update: Mitchison, D.A.; Zhang, Y.

Experience with Phase III Clinical Trials of Antituberculosis Drugs and Regimens: Conclusions and Lessons for the Future: Jindani, A.

Fluoroquinolones in the Management of Tuberculosis: Singh, K.P.; Gillespie, S.H.

Current Standard Treatment: Vernon, A.A.

Tuberculosis Recurrence: Exogenous or Endogenous?: Williams, M. et al.

Second-Line Antituberculosis Drugs: Current Knowledge, Recent Research Findings and Controversies: Schaaf, H.S. et al.

Acquisition, Transmission and Amplification of Drug-Resistant Tuberculosis: Müller, B. et al.

The Treatment of Tuberculosis in Children: Cruz, A.T.; Starke, J.R.

The Future

Issues and Challenges in the Development of Novel Tuberculosis Drug Regimens: Eronju, N.; Ginsberg, A.

Drug Resistance in Mycobacterium tuberculosis: Molecular Mechanisms and Laboratory Susceptibility Testing: Böttger, E.C.

The Role of the Mouse Model in the Evaluation of New Antituberculosis Drugs: Nuernberger, E.L.

Current Issues in Tuberculosis Pharmacokinetics: Elgelund, E.F.; Pelquin, C.A.

Pharmacological Considerations of Antitubercular Agents in Children: Goldman, J.L. et al.

Pharmacogenetics of Antituberculosis Drugs: Aarnoutse, R.

Interactions between Antituberculosis and Antiretroviral Agents: McIlrion, H.; Khoo, S.H.

Diabetes Mellitus and Tuberculosis Treatment: Ruslami, R.; van Crevel, R.

Early Bactericidal Activity of Antituberculosis Agents: Diacon, A.H.; Maritz, J.Z.; Donald, P.R.

Assessment of Whole-Body Bactericidal Activity in the Evaluation of New Antituberculosis Drugs: Wallis, R.S.

Serial Sputum Colony Counting in Drug Development: Sloan, D.; Davies, G.


A New Era in Tuberculosis Treatment: What Does the Future Hold?: Duncan, K.

Author Index / Subject Index

With contributions by some of the most well-known specialists in tuberculosis research

Antituberculosis Chemotherapy

Editors

Peter R. Donald
Paul D. van Helden
The Journal of Innate Immunity is a bimonthly published journal that aims to cover all aspects within the area of innate immunity, including evolutionary aspects, pathogen-host cell molecular interactions, host response and inflammation, complement and coagulation, microbial corruption of innate immunity, molecular genomics, development of vaccines and immunotherapies. The journal features original papers (Research Articles, Clinical Investigations), Reviews/Mini Reviews, Letters to the Editors, Rapid Communications and Short Communications.

Criteria for acceptance are quality, originality, and clarity. The Journal of Innate Immunity will not consider papers that are either preliminary or purely descriptive. Reports on clinical cases are accepted only if they provide novel insight into unresolved problems of innate immunity.

Submission

Only original papers written in English are considered. Manuscripts should be submitted online using the online submission website at www.karger.com/jin (the preferred word-processing package is MS-Word®).

Editorial Office:
Heiko Herwald, PhD
S. Karger AG
Editorial Office ‘Journal of Innate Immunity’
P.O. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 13 57
Fax +41 61 306 14 34
E-Mail jin@karger.com

Conditions

All manuscripts must be accompanied by a covering letter signed on behalf of all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

All manuscripts are subject to editorial review. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of the Journal of Innate Immunity and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the authors’ responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Sections

Papers similar to regular papers, every issue of the journal will have a special section with a thematic focus. Contributions to these special topic sections are very welcome and authors are asked to contact the Editor-in-Chief or the responsible guest editors before submitting a manuscript in order to avoid clashes with other pending papers. For details see the journal content at www.karger.com/jin.

All articles will undergo an in-depth peer-review process.

Original Paper (Research Article/ Clinical Investigation): Submitted manuscripts should be fully documented reports of original research. They must describe significant and original observations.

Review: The normal maximum length of a Review is limited to 5–7 printed pages, i.e. approximately 20 manuscript pages (font 12, double spacing), including 1–3 figures and/or tables. The number of references should not exceed 50. Potential authors are asked to contact the editors before submitting their papers in order to avoid clashes with other pending reviews.

Letter to the Editor: Letters to the Editor concerning articles published in Journal of Innate Immunity may be submitted for publication. They should not be more than one printed page in length. If accepted, the authors of the articles concerned will be given the opportunity to reply.

Short Communication: The general arrangement for short communications is the same as for research papers. The text should also be divided into separate sections formally entitled introduction, methods, results, discussion. These should not be more than 3 printed pages in length including an abstract of up to 50 words.

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute(s) where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as an e-mail address.

Key words: For indexing purposes, a list of 3–10 key words in English is essential.

Abstract: Each paper needs an abstract of up to 200 words describing background, methods, results and conclusions.

Footnotes: Footnotes should be avoided. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180×233 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling (final size), line art drawings one of 800–1,200 dpi. Figure files should not be embedded in a document file but submitted separately.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org). Authors using EndNote® may choose the format setting for Intervirology for the correct format of references.

Examples


(b) Papers published only with DOI numbers: Theoharidès TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Ethics

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925–926]. Information suitable to reveal the subject’s identity is to be avoided. Further, they should also state that animal experiments conform to institutional standards. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Conflict of Interest

All forms of funding and support, including that from companies, and any potential competing financial interests should be acknowledged in the cover letter to the editor when applicable. The statement has to be listed at the end of the article.
The Aging Issue: Editorial

Tamas Fulop

Will We Ever Know What Causes Aging?

Harald Hampel, Simone Lista

Silent Alarm: The Quiet Epidemic of Alzheimer’s Disease

Brian Kennedy

The Digital World’s Silver Lining

KI12305
CEO, Buck Institute for Research on Aging

Author's Choice™

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author's Choice™

S. Karger’s Author's Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.Karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Color Illustrations

During the review process, the decision will be made as to which color illustrations of a manuscript can be reproduced free of charge. Authors will be informed of this at the time of acceptance of their paper.

Video Files

Video files for the Journal of Innate Immunity enhance the online versions. The printed journal remains the archival version. Since it does not contain video files, the latter can only be supplements which improve the reader’s understanding of the paper. In the printed version they should be replaced by a ‘typical’ figure. For further information, please refer to http://www.karger.com/jin_guidelines.

Copy Editing

All manuscripts accepted for publication by Karger are subject to copy editing. Changes introduced by the copy editor and/or questions will be marked in the manuscript so please be sure to check the proofs against the manuscript. The copy edited manuscript will be returned along with the proofs.

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author. No page proofs are supplied.

E-pub First

All articles are published electronically ahead of print with a DOI number and are supplemented later with the definite reference of the printed version. The articles become available immediately after the authors’ approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.

Reprints

An order form and a price list are sent with the proofs. Orders submitted after the release of an article in print are subject to considerably higher prices.

For over 40 years the Karger Gazette has been distributed to a growing audience worldwide. Published once a year in newspaper format, it highlights advances in biomedicine and clinical practice, introduces personalities, portrays research institutes and chronicles milestones in the history of Karger Publishers in a lively and readable style. With invited contributions by experts from all over the world, each issue is devoted to a special topic of current interest.

In the latest issue, read free articles on the causes of the aging process, why aging stops in later adult life, the quiet epidemic of Alzheimer’s Disease, internet use by seniors, and more.

For your free print subscription — gazette@karger.com

Read it online — www.karger.com/gazette

S. Karger AG
Medical and Scientific Publishers
Karger Gazette
Albschlierstrasse 10
CH-4009 Basel
Switzerland
www.karger.com
### General Information

**Subscription Rates:** Subscriptions run for a full calendar year. Prices are given per year.

<table>
<thead>
<tr>
<th>Subscription Type</th>
<th>Print or Online</th>
<th>Print+Online combined</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Personal</strong></td>
<td>CHF 94.–</td>
<td>CHF 142.–</td>
</tr>
<tr>
<td><strong>Print or Online</strong></td>
<td>EUR 76.–</td>
<td>EUR 115.–</td>
</tr>
<tr>
<td><strong>Print and handling</strong></td>
<td>USD 93.00</td>
<td>USD 141.00</td>
</tr>
<tr>
<td><strong>Postage</strong></td>
<td>CHF 43.20 Europe, CHF 62.40 Overseas</td>
<td></td>
</tr>
<tr>
<td><strong>Postage and handling</strong></td>
<td>EUR 33.60</td>
<td>USD 57.60</td>
</tr>
<tr>
<td><strong>Institutional</strong></td>
<td>CHF 1861.–</td>
<td>CHF 2047.–</td>
</tr>
<tr>
<td><strong>Print or Online</strong></td>
<td>EUR 1501.–</td>
<td>EUR 1651.–</td>
</tr>
<tr>
<td><strong>Postage</strong></td>
<td>USD 1843.00</td>
<td>USD 2027.00</td>
</tr>
<tr>
<td><strong>Postage and handling</strong></td>
<td>CHF 54.– Europe, CHF 78.– Overseas</td>
<td></td>
</tr>
<tr>
<td><strong>Print or Online</strong></td>
<td>EUR 42.–</td>
<td>USD 72.00</td>
</tr>
<tr>
<td><strong>Airmail surcharge</strong></td>
<td>CHF 52.50 / USD 49.50</td>
<td></td>
</tr>
</tbody>
</table>

**Back Volumes and Single Issues:** Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

**Bibliographic Indices:** This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

**Photocopying:** This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc., 222 Rosewood Drive Danvers, MA 01923 (USA). A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH–4009 Basel (Switzerland).

---

**Change of Address:** Both old and new address should be sent to the subscription source.

**Subscription Orders:**

Orders can be placed at agencies, bookstores, directly with the Publisher S. Karger AG Medical and Scientific Publishers P.O. Box CH–4009 Basel Switzerland (for courier services only: Allschwilerstrasse 10 CH–4055 Basel) t: +41 61 306 11 11 f: +41 61 306 12 34 e: karger@karger.com w: www.karger.com or further Karger offices or representatives:

- **Germany** S. Karger GmbH Postfach 79095 Freiburg Deutschland (Hausadresse: Wilhelminstrasse 20A, 79098 Freiburg) t: +49 761 45 20 70 f: +49 761 45 20 714 e: information@karger.de w: www.karger.de

- **Japan** Karger Japan, Inc. Shibata Daimon Asahi Bldg. 2F 1-2-23 Shibata Daimon Minato-ku Tokyo 105-0012 Japan t: +81 3 6435 6242 f: +81 3 6435 6244 e: publisher@karger.jp w: www.karger.jp

- **USA** S. Karger Publishers, Inc. 26 West Avon Road P.O. Box 529 Unionville, CT 06085 USA Toll free: +1 800 828 5479 f: +1 860 675 7302 e: karger@net.net

- **France** Librairie Médé-Sciences Sarl 36, bd de Latour-Maubourg 75007 Paris France t: +33 (0) 1 45 51 42 58 f: +33 (0) 1 45 56 07 80 e: medsci@med- sciences.fr w: www.medit-sciences.fr

- **South East Asia, China and Taiwan**

  **Karger Regional Office (Malaysia)**
  CEO Suite Kuala Lumpur Quill 7, 27th Floor Jalang Stesen Sentral 5 KL Sentral Kuala Lumpur 50470 Malaysia t: +60 3 2776 6803 f: +60 3 2776 6999 e: service@karger.cn; t.chew@karger.cn

  **Karger China**
  10th Floor, Twin Towers (East) B12 Jiaoguangwai Avenue Beijing 100022 China t: +86 10 5123 5033 f: +86 10 5123 5122 e: service@karger.cn; t.chew@karger.cn w: www.karger.cn

- **India, Bangladesh, Sri Lanka**

  **Medisence India**
  Plot No. 17, Yusuf Sarai Market B.L. Glass Building, 2nd Floor Sri Aurobindo Marg New Delhi 110 016 India t: +91 11 46029 633 f: +91 11 46029 634 e: medsci.india@gmail.com
Contents

See the journal website for contents
Keystone Symposia conferences are known for their collegial atmospheres where late-breaking research is presented, high-quality interactions occur, and new collaborations are forged. Please visit the meeting web pages for all deadlines and full and current program information. And visit keystonesymposia.org/meetings for information on all of the 53 Keystone Symposia conferences in the 2012-2013 season.

Keystone Symposia on Molecular and Cellular Biology is a 501(c)3 nonprofit organization headquartered in Colorado, USA that is directed and supported by the scientific community.

www.keystonesymposia.org/immunology • 1.970.262.1230 • 1.800.253.0685 (in US & Canada)
The aim of this two days symposium is to review current concepts, technology and present advances in infections in the critically ill patients.

Sepsis, Pulmonary Infections, Basic Research, Pulmonary Infections Treatment and Prophylaxis Therapy of severe infections will be the topics of the main sessions presented by experts who will review and update the new advances on infections in the critically ill patient. At the end of each session a Clinical Controversy, Panel Discussion or Case Report Discussion will be organized.

Organized by
Antonio Artigas, MD
Jean Carlet, MD
Michael Niederman, MD
José Garnacho, MD

www.infections-online.es
CoVAC
The 2nd Conference on
CONTROVERSIES IN VACCINATION IN ADULTS

MUNICH, GERMANY • FEBRUARY 14-17, 2013

Ethan Rubinstein, Canada    Hartmut Lode, Germany
Co-Chairpersons

ABSTRACT SUBMISSION DEADLINE: December 15, 2012
EARLY REGISTRATION UNTIL: JANUARY 2, 2013

MAIN TOPICS:
• Global Evolution of the Pneumococcus and the Impact of Vaccination
• Pneumococcal Vaccine
• Optimizing Pneumococcal Vaccination
• Influenza Vaccines
• Papillomavirus Vaccine and Vaccination in Travel Medicine
• Emerging pathogens and vaccine development
• HIV Vaccine C. Difficile Vaccine
• How to prevent C. difficile colonization and infection?
• Staphylococcal Vaccine and TB Vaccine
• VZV Vaccine

covac@comtecmed.com    www.comtecmed.com/covac

CME Accredited
16 Points
World Immune Regulation Meeting - VII
13 - 16 March 2013 Davos, Switzerland
“Innate and Adaptive Immune Response and Role of Tissues in Immune Regulation”

Register now on www.wirm.ch

Topics:

Basic Mechanisms
- Innate immune response receptors
- Dendritic cell subsets & immune regulation
- B cell subsets & immune regulation
- NK cells & NK-T cells
- Transcriptional regulation of immune tolerance & reactivity
- Development of effector & regulatory T cells
- T & B cell memory & immune regulation
- Th17 cells functions & effector mechanisms & interaction with other cells
- Chemokines & receptors in peripheral tolerance
- Apoptosis in the regulation of immune responses
- Mechanisms of immune privilege
- The role of microRNAs in immune regulation & effector functions
- Immune regulatory mechanisms related to resident tissue cells
- Epigenetic-mediated immune memory

Focus on clinical application, drug discovery & novel biotechnological developments
- Hygiene hypothesis in immune regulation
- Regulatory & effector T cell subsets & cytokines: from bench to bedside
- Tolerating the nervous system: a delicate balance
- Immune response to parasites
- Tumor antigen-specific immune regulation
- Immune tolerance & autoimmune
- Immune tolerance in allergy & asthma
- Immune regulation in organ transplantation tolerance
- Experimental models of inducing & breaking peripheral tolerance
- Mucosal tolerance & intestinal homeostasis
- Development of novel vaccines & drugs
- Immunomodulation in vivo, “biologicals”
- Cellular therapies including stem cell therapies

Speakers:

Marcus Altfeld
Francesco Annunziato
David Artis
Jacques Banchereau
Burkhard Becher
Jay Berzofsky
Thomas Casale
Charles A. Dinarello
Richard Flavell

Ronald Germain
Gökhan Hotamisligil
Yoshihiro Kawaoka
Mitchell Kronenberg
Matthew F. Krummel
Jean-Paul Latgé
Bernard Malissen
Polly Matzinger

Claudia Mauri
Sarkis K. Mazmanian
Mihai G. Netea
Luke O’Neill
Daniel Pinschwer
Harald Renz
Luigina Romani
Pamela L. Schwartzberg

Hergen Spits
Warren Strober
Antonio Uccelli
Derya Unutmaz
Ari Waisman
Jean-Claude Weill
Xiaoning Xu
Lars Zender

SWISS
Official Carrier
VI WORLD ASTHMA, ALLERGY & COPD FORUM
London, UK
April 27–30, 2013

PROGRAM COMMITTEE CO-CHAIRS

Walter Canonica  Adnan Custovic  Stephen Holgate  Allen Kaplan  Revaz Sepiashvili
Italy  UK  UK  USA  Russia

KEYNOTE HONORARY LECTURES

ALAIN DE WECK HONORARY LECTURE by Adnan Custovic
Allergens and asthma

ALBERT OEHLING HONORARY LECTURE by Allen Kaplan
Asthma as a complex inflammatory disease

PROCEEDINGS

Congress Proceedings will be published by the Medimond S.r.l – Monduzzi Editore International Proceedings Division. Such a publication will not only increase the success of the individual presentations and the Forum in general, but will also help to publicize the contents of the Forum to a much wider audience.

The Volume is ISBN coded and indexed in Conference Proceedings Citation Index published by Thomson Reuters – Philadelphia formerly Institute for Scientific Information ISI.

Invitations to contribute to the Proceedings Book will be e-mailed to those congress attendees whose abstracts are accepted either for oral or poster presentation.

CME CREDITS

CME credits will be available for the VI WORLD ASTHMA, ALLERGY & COPD FORUM participants. This Congress will be accredited by the European Board for Accreditation in Pneumology (EBAP). European Accreditation is granted by EBAP following the EAACME Standards (D9908). Through a reciprocity agreement signed in 1999 by the American Medical Association (AMA) and the UEMS, EAACME credits will be available to US doctors. EAACME credits are recognized in Europe and by the AMA towards the Physician’s Recognition Award (PRA).

The Congress will be hosted by Hilton London Metropole Hotel, Winner of the prestigious ‘Best Business Hotel’, England, award at the Business Destination Travel Awards 2011, which is one of Europe’s largest hotel and conference centers in the heart of London. With superb transportation links, the hotel is just 20 minutes from Heathrow Airport via the Heathrow Express at Paddington Station. Eurostar Service to Europe at St. Pancras International Station.

Just 10 minutes’ walk from the West End and Oxford Street and a 10 minute tube ride from Westfield Shopping Centre, the Hilton London Metropole hotel is the ideal destination for the business and leisure guest.

CONGRESS SECRETARIAT

WORLD IMMUNOPATHOLOGY ORGANIZATION

(7-495) 735-1414
Fax  (7-495) 735-1414
E-mail  info@wipocis.org (Registration, Accommodation, Tours)
        wipocis@mail.ru (Abstracts, Congress Program)

www.wipocis.org
FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES CONGRESS 2013

Mechanisms in Biology

DISTINGUISHED PLENARY SPEAKERS

Aaron Ciechanover (Israel)
The Nobel Prize in Chemistry 2004

Jules Hoffmann (France)
The Nobel Prize in Physiology or Medicine 2011

Robert Huber (Germany)
The Nobel Prize in Chemistry 1988

Roger D. Kornberg (USA)
The Nobel Prize in Chemistry 2006

Jean-Marie Lehn (France)
The Nobel Prize in Chemistry 1987

Richard Roberts (USA)
The Nobel Prize in Physiology or Medicine 1993

Jack W. Szostak (USA)
The Nobel Prize in Physiology or Medicine 2009

John E. Walker (UK)
The Nobel Prize in Chemistry 1997

Kurt Wüthrich (Switzerland, USA)
The Nobel Prize in Chemistry 2002

Ada E. Yonath (Israel)
The Nobel Prize in Chemistry 2009

MAIN TOPICS

Mechanisms of Genetic Control
  • Organization of eukaryotic genomes
  • RNA world
  • Biochemistry of DNA modification and repair
  • Quantitative genomics
  • Nucleic acid targets and therapeutics

Biocatalytic Mechanisms and Protein Dynamics
  • Biocatalysis: General problems
  • Protein structure and folding
  • Protein dynamics
  • Enzymes reacting with organophosphates
  • Alexander Braunstein Memorial Symposium: Enzymes, cofactors, mechanisms

Mechanisms of Communication and Signaling
  • Ion channel signaling:
    From spatial structures to physiological mechanisms
  • Membrane transport and secretion: From nephrons to neurons
  • Biochemistry of stress response
  • “Mitochondriology”: New approaches in bioenergetics
  • Cell mechanisms of proteolysis

Molecular Mechanisms of Disease
  • Biochemistry for medicine: Drug design and diagnostics
  • Biochemistry of neoplastic transformations
  • Mechanisms of G protein signaling
  • Biochemistry of neurodegeneration
  • Photoreception and biochemistry of vision

Biochemical Mechanisms of Immune Defense
  • Stem cells: Fundamentals and applications
  • Molecular basis of autoimmunity
  • Immunochemistry and bioengineering
  • B cells in inflammation and disease

General Aspects of Biochemistry
  • Proteomics and peptidomics
  • Metabolism of marine organisms: Structure and activities
  • Signaling pathways in plants
  • Glycobiology: Carbohydrate–protein recognition
  • Bioinformatics
  • Systems biology
  • Biogenic polyamines in cell metabolism
  • Biochemistry of invertebrates
  • Bioengineering: Fundamentals and application

IMPORTANT DATES

Start of online registration and abstract submission
January 5, 2013

Early Registration deadline
April 5, 2013

Regular Registration deadline
June 1, 2013

Abstract Submission deadline
April 15, 2013

WWW.FEBS-2013.ORG
info@febs-2013.org (registration, accommodation)
Program_Com@febs-2013.org (abstracts, program)
YSF@febs-2013.org (Young Scientists Forum)

Do not miss a chance to visit St. Petersburg in the high season of famous White Nights!
THEME:

1. ILYA METchnikoff Honorary Lecture
   by Allan Goldstein
   THYMOSINS IN HEALTH AND DISEASE

2. PAUL EHRlich Honorary Lecture
   by Sergio Romagnani
   MAIN FEATURES OF HUMAN TH17 CELLS

DEADLINES

- For submission of Abstracts: June 1, 2013
- For submission of Early Registration: November 30, 2012
- For submission of Advance Registration: March 1, 2013

CME CREDITS

CME credits will be available for the VIII WORLD CONGRESS OF IMMUNOPATHOLOGY, RESPIRATORY ALLERGY & ASTHMA (Dubai, UAE; October 12–15, 2013) participants. This Congress will be accredited by the European Accreditation Council for Continuing Medical Education (EACCME), European Board of Pneumology (EBAP). European accreditation is granted by EBAP following the EACCME standards (D9908). The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA).

CONGRESS SECRETARIAT

- WORLD IMMUNOPATHOLOGY ORGANIZATION
- (7-495) 735-1414
- Fax (7-495) 735-1441
- E-mail info@wipocis.org (Registration, Accommodation, Tours etc.)
- E-mail wipocis@mail.ru (Abstract Submission, Scientific Program)

Online Registration and Abstract Submission

www.wipocis.org
Contents

Preface: Ohno, I.

Plenary Review
Pathophysiologic Role of Histamine: Evidence Clarified by Histidine Decarboxylase Gene Knockout Mice: Ohtsu, H.

Original Papers
Murine T Cell-Derived Contractile Activity for Bronchial Smooth Muscle Cells: Abe, A. et al.
Eosinophil Granular Proteins Damage Bronchial Epithelial Cells Infected with Respiratory Syncytial Virus: Kata, M. et al.
Alternaria Fungus Induces the Production of GM-CSF, Interleukin-6 and Interleukin-8 and Calcium Signaling in Human Airway Epithelium through Protease-Activated Receptor 2: Matsuwaki, Y. et al.
NFAT1 and NFAT2 Differentially Regulate IL-17A Expression in Human T Cells: Kaminuma, O. et al.

Higher Sensitivity of Male CD4+ T Cells to Suppressive Effects of CD8+ T Cells on IL-5 Production Compared to Female CD4+ T Cells: Okuyama, K. et al.
Roles of CRTH2+ CD4+ T Cells in Immunoglobulin G4-Related Lacrimal Gland Enlargement: Saito, Y. et al.
Elevated Levels of Interleukin-33 in the Nasal Secretions of Patients with Allergic Rhinitis: Asaka, D. et al.
1,25-Dihydroxyvitamin D3 Upregulates Functional C-X-C Chemokine Receptor Type 4 Expression in Human Eosinophils: Hiraguchi, Y. et al.
Possible Regulatory Role of Galectin-9 on Ascaris suum-Induced Eosinophilic Lung Inflammation in Mice: Katoh, S. et al.
Inhibition of Allergen-Induced Airway Inflammation by Low Dose Oral Immunotherapy with Transgenic Rice Seeds Independently of Immunoglobulin E Synthesis: Saeki, M. et al.

Novel Insights from Clinical Practice
Elevated Numbers of Cells Producing Interleukin-5 and Interleukin-10 in a Boy with Kimura Disease: Hosoki, K. et al.
Eosinophilic Gastroenteritis due to Cow’s Milk Allergy Presenting with Acute Pancreatitis: Suzuki, S. et al.
Eosinophilic Gastrointestinal Disorder in an Infant with Feeding Dysfunction: Yamada, Y. et al.

Reviews
Obesity and Eosinophilic Inflammation: Does Leptin Play a Role?: Takeda, M. et al.
Critical Roles of IκB Kinase Subunits in Mast Cell Degranulation: Nakagomi, D. et al.
Neutrophilic Inflammation in Severe Asthma: Nakagami, K. et al.

Abstracts of Lectures at the Workshop
List of Lectures by Speakers Who Have Not Submitted Their Manuscripts

Author Index
Subject Index
The forum for innovative research in virology

Intervirology

Editor-in-Chief
J.-C. Manuguerra, Paris

Associate Editors
I. Leclercq, Paris
R. Medeiros, Belém

Editor for Japan/S. Asia
O. Hino, Tokyo

Selected contributions
- Prevalence of Herpes Simplex Virus Type 2 in Different Risk Groups: Thirty Years after the Onset of HIV: Reinheimer, C.; Doerr, H.W.
- Periventricular Demyelination and Axonal Pathology Is Associated with Subependymal Virus Spread in a Murine Model for Multiple Sclerosis: Kummerfeld, M.; Seehusen, F.; Klein, S.; Ulrich, R.; Kreutzer, R.; Gerhauser, I.; Herder, V.; Baumgärtner, W.; Beineke, A.
- Reclassification of Giant Viruses Composing a Fourth Domain of Life in the New Order Megavirales: Colson, P.; de Lamballerie, X.; Fournous, G.; Raoult, D.
- Detection of Mimivirus in Bronchoalveolar Lavage of Ventilated and Nonventilated Patients: Costa, C.; Bergallo, M.; Astegiano, S.; Terlizzi, M.E.; Sidoti, F.; Saldidoro, P.; Cavallo, R.
- A Short Hairpin Loop-Structured Oligodeoxynucleotide Targeting the Virion-Associated RNase H of HIV Inhibits HIV Production in Cell Culture and in huPBL-SCID Mice: Heinrich, J.; Schols, D.; Moelling, K.
- Targets for Inhibition of HIV Replication: Entry, Enzyme Action, Release and Maturation: Sierra, S.; Walter, H.

Intervirology covers progress in both basic and clinical virus research, and aims to provide a forum for the various disciplines within virology. Issues publishing original papers alternate with thematic issues, focusing on clearly defined topics. This thematic concentration serves to make timely reviews, research reports and controversy easily accessible to both specialists in the field and those who want to keep track of the latest developments outside their own area of interest. In addition to original papers, regular issues publish short communications and letters to the editor to provide readers with a forum for the exchange of ideas and comments. The scope encompasses work on the molecular biology of human and animal viruses, including genome organization and regulation, and the structure and function of viral proteins. The pathogenesis, immunology, diagnosis, epidemiology, and prophylaxis and therapy of viral diseases are considered.

More information at www.karger.com/int
- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Intervirology
2013. Volume 56
6 issues per volume
Language: English
ISSN 0300–5526 (print)
e-ISSN 1423–0100 (online)

Listed in bibliographic services, including Current Contents-Life Sciences, MEDLINE, Biological Abstracts, EMBASE/Excerpta Medica, Chemical Abstracts

Impact Factor: 2.337
Cover illustration
Confocal microscopy image of a nontypeable *Haemophilus influenzae* strain 86-028NP biofilm recovered from the middle ear of a chinchilla 21-days following bacterial challenge. A serial section of the biofilm was immunolabeled with rabbit anti-chinchilla beta-defensin-1 (cBD-1) to visualize cBD-1 (red). Bacteria and host cells were stained with a cellular phospholipid membrane stain and appear green. Extracellular DNA (eDNA) was labeled with DAPI and is pseudo-colored white. Note the dense meshwork of eDNA throughout the biofilm matrix as well as the relative abundance of labeled cBD-1 on strands of eDNA demonstrating that this peptide co-localized with DNA in an in vivo nontypeable *Haemophilus influenzae* biofilm. Image kindly provided by Eric A. Jones, Columbus, Ohio, USA.